Pfizer Inc. (PFE)
After hours:
| Previous Close | 25.26 |
| Open | 25.33 |
| Bid | 25.41 x 4000 |
| Ask | 25.46 x 2900 |
| Day's Range | 25.20 - 25.54 |
| 52 Week Range | 25.20 - 40.37 |
| Volume | |
| Avg. Volume | 42,220,991 |
| Market Cap | 143.829B |
| Beta (5Y Monthly) | 0.57 |
| PE Ratio (TTM) | 68.65 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.68 (6.65%) |
| Ex-Dividend Date | May 09, 2024 |
| 1y Target Est | N/A |
- Investor's Business Daily
A Big Week For The Stock Market: Apple, Amazon, Big Pharma And The Fed
Stock market investors brace for a big week of earnings and econ as Apple, Amazon, Big Pharma and The Fed all line up to deliver news.
- Investor's Business Daily
Pfizer Wins FDA Approval For $3.5 Million Gene Therapy, Rivaling CSL, Uniqure
The FDA approved Pfizer's hemophilia gene therapy on Friday. But Pfizer stock only inched ahead on the approval early Friday.
- Barrons.com
Pfizer Receives FDA Approval for Bleeding Disorder Treatment
Pfizer has received approval from the Food and Drug Administration for a rare genetic bleeding disorder treatment—the drug-maker’s first gene therapy to be approved in the U.S. The treatment, Beqvez, is for adults with moderate to severe hemophilia B—a disorder that prevents normal blood clotting—and will be available by prescription to eligible patients this quarter, according to the company. “Many people with hemophilia B struggle with the commitment and lifestyle disruption of regular FIX infusions, as well as spontaneous bleeding episodes, which can lead to painful joint damage and mobility issues,” said Adam Cuker, director of University of Pennsylvania’s Comprehensive Hemophilia and Thrombosis Program.
